Senographe 2000D wins expedited review In September, the Food and Drug Administration sparked controversy with its suggestion that full-field digital mammography vendors submit a premarket approval application (PMA) for their devices, rather than
Senographe 2000D wins expedited review
In September, the Food and Drug Administration sparked controversy with its suggestion that full-field digital mammography vendors submit a premarket approval application (PMA) for their devices, rather than a 510(k) application. As the news spread, industry observers expressed concern that a PMA requirement for digital mammography would further delayor even derailthe technologys commercialization, since vendors might not have the ability to gather PMA data quickly (SCAN 10/13/99).
That concern may soon prove unfounded. Less than two months after the FDAs communication, the agency received a PMA submission from GE Medical Systems for its full-field digital unit, Senographe 2000D. GE submitted its application to the FDA on Oct. 29, and was granted expedited review, according to the company.
On Dec. 16, the FDAs Radiological Devices Panel of the Medical Devices Advisory Committee will hold a public meeting in Rockville, MD, to discuss GEs submission and compose a recommendation to the agency as to whether to clear the device. After the meeting, the FDA will receive the panels recommendation and, along with its own scientific investigation data, make a decision about the application.
Although the company declined to comment on how many patients it included in its clinical data for the PMA, it has imaged more than 8000 patients on 18 systems installed outside the U.S., according to Amy Hobert, Americas marketing manager for breast imaging. GE began European shipments of Senographe 2000D in February, installing its first commercial unit at Charite Hospital in Berlin (SCAN 3/17/99).
In its September communication to vendors, the FDA not only suggested the PMA for digital mammography units, but also stated that part of the package would be a required, non-enriched, post-approval screening trial of perhaps as many as 20,000 patients. Acknowledging such a trials time and financial cost, the agency emphasized that it would accept proposals from manufacturers for joint studies, potentially overseen by a third party. Without specifying how it will address this requirement, GE made clear that it is prepared to comply, according to spokesperson Charles Young.
Well follow whatever guidelines the FDA sets out, Young said. Were aware that a post-screening study is a possibility.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
New Research Examines Socioeconomic Factors with Mammography No-Shows
April 10th 2024Patients with Medicaid or means-tested insurance were over 27 percent more likely to miss mammography appointments, and only 65 percent of women with three of more adverse social determinants of health had a mammography exam in a two-year period covering 2020 and 2021, according to new research and a report from the CDC.
Mammography Study: AI Improves Breast Cancer Detection and Reduces Reading Time with DBT
April 3rd 2024An emerging artificial intelligence (AI) model demonstrated more than 12 percent higher specificity and reduced image reading time by nearly six seconds in comparison to unassisted radiologist interpretation of digital breast tomosynthesis (DBT) images.